Stereotactic Radiation Therapy Shows Superior Quality of Life Benefits Over Hippocampal-Avoidance WBRT in Brain Metastases Trial

A landmark multicenter phase 3 randomized trial has demonstrated that stereotactic radiation therapy (SRT) provides superior quality of life outcomes compared to hippocampal-avoidance whole brain radiation therapy (HA-WBRT) in patients with multiple brain metastases, addressing a critical gap in treatment options for this challenging patient population.

Trial Design and Patient Population

The study, conducted between April 2017 and May 2024, enrolled 196 patients aged 18 to 80 years, with 98 patients randomized to each treatment arm. All participants had 5 to 20 brain metastases from solid primary cancers, excluding small cell lung cancer, with no prior brain radiation or leptomeningeal disease. The trial specifically targeted patients with more than 4 lesions, a population for which limited data previously existed regarding SRT efficacy.

Primary Endpoint Results

The study's primary objective was to assess patient-reported symptom severity and interference using the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) over a six-month period. Results demonstrated that the SRT arm exhibited significantly lower overall symptomatology and interference compared to the HA-WBRT arm, successfully meeting the study's primary endpoint. Specifically, SRS/SRT led to lower symptom severity and less interference in daily function.

Clinical Significance and Current Treatment Landscape

According to Dr. Ayal Aizer, a brain radiation oncologist at Brigham and Women's Hospital and Dana-Farber Cancer Institute, while SRT has previously shown improved quality of life over whole brain radiation therapy for patients with fewer brain metastases, this study provides crucial evidence for patients with higher lesion counts. The trial also represents the first direct comparison between SRT and HA-WBRT, a technique known to be superior to traditional WBRT.

Call for Personalized Treatment Approaches

Dr. Aizer emphasizes that many questions remain unanswered in the field of brain metastases radiation treatment, particularly regarding personalization of care. "Those in medical oncology have excelled at tailoring therapies for specific patient subsets. For example, in non-small cell lung cancer, mutational assays and immune markers guide systemic treatment decisions, moving away from a one-size-fits-all approach," Aizer noted.

The field urgently needs to reach a similar level of personalization for patients with brain metastases, according to Aizer. Currently, despite some minor variations, the approach to radiation for brain metastases is largely standardized. "Greater personalization of care would undoubtedly be beneficial," Aizer stated, emphasizing that achieving this requires better data to inform individualized strategies.

Pre-Surgical SRT as Alternative Strategy

Complementing these findings, researchers led by Dr. Debra Nana Yeboa conducted a separate Phase III clinical trial examining pre-surgical versus post-surgical SRT in 103 patients with resectable brain metastases. Preliminary results show that pre-surgical SRT resulted in similar 30-day post-surgical toxicity outcomes compared to post-surgical SRT, with potentially shorter time between surgery and radiation.

These findings suggest that giving SRT before surgery represents a promising, potentially safe strategy for patients with brain metastases, offering clinicians additional treatment sequencing options.

Future Research Directions

A key objective for the coming years is to gather data that enables clinicians to tailor radiation for brain metastases to individual patient needs and then rigorously test these personalized strategies in clinical trials. This approach mirrors the precision medicine advances that have transformed medical oncology, where treatment decisions are increasingly guided by molecular markers and patient-specific factors rather than standardized protocols.